Clinical Trial Update: A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies [Phase 3]

View source ↗

Summary

Phase 3 trial comparing darolutamide with androgen deprivation therapy (ADT) versus placebo with ADT in men with hormone-sensitive prostate cancer and rising PS…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Androgen deprivation therapy (Androgen deprivation therapy)
• Darolutamide (Nubeqa) (darolutamide)

Snippet

Sponsor: Bayer | Conditions: Biochemically Recurrent Prostate Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING